Vutrisiran Market Report 2026

Vutrisiran Market Overview

• Vutrisiran market size has reached to $0.67 billion in 2025 • Expected to grow to $1.18 billion in 2030 at a compound annual growth rate (CAGR) of 12% • Growth Driver: Rising Research And Development (R&D) Investments Fuel Growth Of The Market • Market Trend: Expansion Into Cardiomyopathy Through FDA Approval Drives Growth in the Vutrisiran Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Vutrisiran Market?

Vutrisiran is a small interfering RNA (siRNA) therapy for hereditary transthyretin-mediated (hATTR) amyloidosis. It silences the transthyretin (TTR) gene, reducing abnormal TTR protein deposits that cause polyneuropathy and organ damage. Vutrisiran helps slow disease progression and improve neurological function, mobility, and quality of life with a longer dosing interval. The main types of drug classes for the vutrisiran are antisense oligonucleotide, nucleic acids, nucleotides, nucleosides, and others. Antisense oligonucleotides (ASOs) are synthetic short DNA or RNA molecules that target specific mRNA sequences to regulate gene expression. It is administered through various routes of administration, such as oral, injectable, and subcutaneous, for several patient demographics, including pediatric, adult, and geriatric. It is distributed through various distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others.

What Is The Vutrisiran Market Growth Forecast?

The vutrisiran market size is expected to see rapid growth in the next few years. It will grow to $1.18 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to growing rare disease awareness, expansion of rna therapeutics pipeline, rising adoption of long-acting therapies, increased genetic screening, growth in specialty care centers. Major trends in the forecast period include growing adoption of rna interference therapies, increased focus on rare genetic disorders, expansion of long-interval dosing treatments, rising demand for targeted amyloidosis therapies, increased use of subcutaneous rna drugs.

Global Vutrisiran Market Segmentation

1) By Drug Class: RNA Interference (RNAi) Therapeutics, GalNAc-Conjugated Nucleic Acid Drugs, Synthetic RNA-Based Therapeutics 2) By Route Of Administration: Injectable, Subcutaneous 3) By Patient Demographics: Adult, Geriatric 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels Subsegments: 1) By RNA Interference (RNAi) Therapeutics: Small Interfering RNA (siRNA) Drugs, Gene-Silencing RNA Therapies 2) By GalNAc-Conjugated Nucleic Acid Drugs: GalNAc-Conjugated siRNA Therapies, Hepatocyte-Targeted RNA Therapeutics 3) By Synthetic RNA-Based Therapeutics: Chemically Modified RNA Therapeutics, Long-Acting RNA Therapeutics

What Is The Driver Of The Vutrisiran Market?

The increasing investment in research and development is expected to propel the growth of the vutrisiran market going forward. Research and development refers to innovating and improving products, services, or processes through systematic investigation and experimentation. The increasing investment in research and development (R&D)is due to government initiatives and funding, growing healthcare and pharmaceutical needs, sustainability, and environmental concerns. Research and development funding allows pharmaceutical companies to conduct clinical trials, demonstrating the drug's long-term benefits and safety, leading to broader regulatory approvals. Additionally, RNA interference (RNAi) technology advancements improve the drug's precision, reducing side effects and increasing patient adoption. For instance, April 2025, Office for National Statistics, a UK-based government department, the UK government’s net spending on research and development (R&D) reached approximately US $22.9 billion (£17.4 billion) in 2023, up from around US $20.0 billion (£16.1 billion) in 2022. Therefore, the increasing investment in research and development is driving the growth of the vutrisiran.

Key Players In The Global Vutrisiran Market

Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc

Global Vutrisiran Market Trends and Insights

Major companies operating in the vutrisiran market are expanding its use into cardiomyopathy via regulatory approval, such as supplemental indication for ATTR CM, to broaden the patient base and maximize long-term value. A supplemental new drug application (sNDA) is a regulatory filing that extends an approved drug's use to new indications. For instance, in March 2025, Alnylam Pharmaceuticals, a US-based biotech company, received FDA approval for AMVUTTRA (vutrisiran) in adult patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM), becoming the first RNAi therapeutic approved for both polyneuropathy and cardiomyopathy forms of the disease. Therefore, the extension into cardiomyopathy is a key trend driving growth in the vutrisiran market by increasing its clinical reach and patient access.

What Are Latest Mergers And Acquisitions In The Vutrisiran Market?

In April 2024, Medison Pharma, an Israel-based pharmaceutical company, partnered with Alnylam Pharmaceuticals Inc. to expand the commercialization of RNAi therapeutics. The partnership aims to enhance global access to Alnylam's groundbreaking RNAi therapies, especially for patients with rare diseases, by utilizing Medison's integrated commercialization platform across various regions, including LATAM, APAC, and other international markets. Alnylam Pharmaceuticals, Inc. is a US-based pharmaceutical company that manufactures vutrisiran.

Regional Insights

North America was the largest region in the vutrisiran market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vutrisiran Market?

The vutrisiran market consists of sales of pre-filled syringes and vials for subcutaneous injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vutrisiran Market Report 2026?

The vutrisiran market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vutrisiran industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.